Evidence map›Paper›PMID 26339061›Full record

ArticleJournal of virology2015

STAT3 Regulates Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus.

Christine A King, Xiaofan Li, Arturo Barbachano-Guerrero, Sumita Bhaduri-McIntosh

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. KAP1 in antiviral immunity: dual roles in viral silencing and immune regulation.Frontiers in cellular and infection microbiology · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Christine A KingDepartment of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, USA kingch@upstate.edu sumita.bhaduri-mcintosh@stonybrookmedicine.edu.
Xiaofan LiDivision of Infectious Diseases, Department of Pediatrics, Stony Brook University School of Medicine, Stony Brook, New York, USA.
Arturo Barbachano-GuerreroDepartment of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, USA.
Sumita Bhaduri-McIntoshDivision of Infectious Diseases, Department of Pediatrics, Stony Brook University School of Medicine, Stony Brook, New York, USA Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York, USA kingch@upstate.edu sumita.bhaduri-mcintosh@stonybrookmedicine.edu.
Stony Brook University · USSUNY Upstate Medical University · US

Funding

Host determinants of Epstein-Barr virus lytic cycle activationR01AI113134 · NIAID · UNIVERSITY OF FLORIDA · PI BHADURI-MCINTOSH, SUMITA · 2014 to 2018
$1.9M
NIAID NIH HHS AI113134NIAID NIH HHS R01 AI113134
6 · The paper itself

Abstract

unlabelledLytic activation of Kaposi's sarcoma-associated herpesvirus (KSHV) from latency is a critical contributor to pathogenesis and progression of KSHV-mediated disease. Development of targeted treatment strategies and improvement of lytic-phase-directed oncolytic therapies, therefore, hinge on gaining a better understanding of latency-to-lytic-phase transition. A key observation in that regard, also common to other herpesviruses, is the partial permissiveness of latently infected cells to lytic-cycle-inducing agents. Here, we address the molecular basis of why only some KSHV-infected cells respond to lytic stimuli. Since cellular signal transducer and activator of transcription 3 (STAT3) is constitutively active in KSHV-associated cancers, KSHV activates STAT3, and STAT3 has been found to regulate lytic activation of Epstein-Barr virus (EBV)-infected cells, we asked if STAT3 contributes similarly to the life cycle of KSHV. We found that high levels of STAT3 correlate with the refractory state at the single-cell level under conditions of both spontaneous and induced lytic activation; importantly, STAT3 also regulates lytic susceptibility. Further, knockdown of STAT3 suppresses the cellular transcriptional corepressor Krüppel-associated box domain-associated protein 1 (KAP1; also known as TRIM28), and suppression of KAP1 activates lytic genes, including the viral lytic switch RTA, thereby linking STAT3 via KAP1 to regulation of the balance between lytic and latent cells. These findings, taken together with those from EBV-infected and, more recently, herpes simplex virus 1 (HSV-1)-infected cells, cement the contribution of host STAT3 to persistence of herpesviruses and simultaneously reveal an important lead to devise strategies to improve lytic-phase-directed therapies for herpesviruses. IMPORTANCE: Lytic activation of the cancer-causing Kaposi's sarcoma-associated herpesvirus (KSHV) is vital to its life cycle and causation of disease. Like other herpesviruses, however, a substantial fraction of latently infected cells are resistant to lytic-phase-inducing stimuli. Investigating the molecular basis for this refractory state is essential for understanding how the virus persists and how it causes disease and to guide efforts to improve treatment of KSHV-mediated diseases. We found that, like two other herpesviruses, EBV and HSV-1, KSHV exploits the cellular transcription factor STAT3 to regulate the susceptibility of latently infected cells to lytic triggers. These findings highlight a common STAT3-centered strategy used by herpesviruses to maintain persistence in their hosts while also revealing a key molecule to pursue while devising methods to improve herpesvirus lytic-phase-directed therapies.

Indexed as

Cell Line, TumorGene Expression Regulation, ViralHerpesvirus 8, HumanHumansHuman Umbilical Vein Endothelial CellsPyridinesRepressor ProteinsRNA InterferenceRNA, Small InterferingSarcoma, KaposiSTAT3 Transcription FactorTripartite Motif-Containing Protein 28TyrphostinsVirus ActivationVirus LatencyPyridinesRepressor ProteinsRNA, Small InterferingSTAT3 protein, humanSTAT3 Transcription FactorTRIM28 protein, humanTripartite Motif-Containing Protein 28TyrphostinsWP1066

Identifiers

PMID26339061
PMCPMC4645641
OpenAlexW1795403715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.